Differences in Epidermal Growth Factor Receptor Gene Mutations and Relationship with Clinicopathological Features in NSCLC Between Uygur and Han Ethnic Groups

Zhang, Yan; Wang, Qiang; Han, Zhijie; Li, Shan

doi:10.7314/apjcp.2013.14.5.2879

Cited by 7 publications

(7 citation statements)

References 15 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The difference of EGFR mutation rate between females and males may be caused by higher smoking rate in males. In addition, lymph nodes involvement was reported with EGFR mutation in some studies (Shi et al, 2014;Zheng et al, 2014), P and T stages were also reported correlated with EGFR mutation (Tomita et al, 2014), while our studies indicated no association of EGFR mutation with pathological stage, lymph nodes and distant metastasis, consistent with other studies (Sahoo et al, 2011;Zhang et al, 2013;Tian et al, 2014;Zhao et al, 2014;Zheng et al, 2014), suggesting constant impact of EGFR mutation during the whole pathogenic process from the very beginning.…”

Section: Discussionsupporting

confidence: 91%

Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China

Zhou¹,

Song²,

He³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Aims: To investigate the distribution of epidermal growth factor receptor (EGFR) mutations, and explore any relationships with clinical characteristics in non-small-cell lung carcinoma (NSCLC) patients. Materials and Methods: EGFR mutations were assessed by ADx-ARMS in 261 NSCLC patients from West China Hospital of Sichuan University. Relationships between EGFR mutation and clinical characteristics were analyzed by SPSS. Results: The EGFR mutation rate was 48.7% (127/261), 19-del and L858R mutations occurred predominantly, accounting for 33.1% and 40.9%, respectively, in mutated cases. Moreover, 10.2% patients were found to carry double mutations. EGFR mutations occurred more frequently in women (57.5%) than in men (41.8%) (P=0.01), and were more frequent in non-smokers (61.2%) than in former or current smokers (31.2%) (P<0.00). In addition, they were more common in adenocarcinomas (52.8%) and adenosquamous carcinomas (42.8%) than in squamous cell carcinomas (14.8%) (p<0.00). However, only smoking history and pathological types, rather than gender, proved to be associated with EGFR mutations on multivariate logistic regression analysis. No significant differences in pathological stage and metastasis status were found between EGFR wild-type and mutated cases, although EGFR mutation type was related to pathological type (p=0.00) -19-del, L858R and other mutation types respectively occurred in 34.2%, 42.5% and 23.3% of adenocarcinomas, but in 14.3%, 0% and 85.7% of non-adenocarcinomas. Conclusions: The EGFR mutation rate was 48.7% in NSCLCs in Southwest China, so that nearly 40% patients might benefit from targeted therapies. Smoking status and pathological types were independent predictors of EGFR mutation, while EGFR mutation type was related to only pathological type, rather than smoking status.

show abstract

Section: Discussionsupporting

confidence: 91%

Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China

Zhou¹,

Song²,

He³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…As the ethnic minorities have distinct life-styles, growing backgrounds, diets and living conditions compared with Han population, the genetic profiles may also differ. For example, Uyghur population, mainly living in North-west of China, had significantly lower EGFR mutation rate than Han population (12% vs. 55.1%) (143). Therefore, these experiences and treatment strategies cannot be directly generalized to other East Asians, namely Mongolians and North Koreans, and Chinese ethnic minorities, and further studies are still needed in these populations.…”

Section: Her2 Mutationsmentioning

confidence: 99%

Lung cancer in never smokers—the East Asian experience

Zhou

2018

Transl. Lung Cancer Res.

131

View full text Add to dashboard Cite

Approximately one third of all lung cancer patients in East Asia are never-smokers. Furthermore, the proportion of lung cancer in never smokers (LCINS) has been increasing over time. Never-smokers are more often diagnosed with adenocarcinoma in East Asia, a subtype largely defined by oncogenic drivers. In this subgroup of patients, as high as 90% of patients have been found to harbor well-known oncogenic mutations and can be successfully managed with targeted therapies inhibiting specific oncogenic mutant kinases. EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment has been the most important targeted therapy in lung adenocarcinoma from East Asian never-smokers as approximately 70% of these patients have the opportunity to receive EGFR-TKI treatment. Lung squamous cell carcinoma (SQCC) and small cell lung cancer (SCLC) are two common histologic types of smoking-related non-small cell lung cancer (NSCLC). The proportion of never-smokers with SQCC and SCLC in East Asian patients seems to be higher than that in Caucasian patients. Recent studies also suggest that lung SQCC and SCLC in never-smokers may be distinct subtypes. Therefore, better understanding of the biologic characteristics of these subtypes of patients may provide new insights for the treatment. In this review, we will provide an overview of East Asian experience in the treatment of advanced, never-smoking lung cancer, focusing on etiologic factors in the development of LCINS, targeted therapy for never-smokers with adenocarcinoma, distinct characteristics of never-smokers with lung SQCC and SCLC, and the role of immunotherapy in never-smokers with NSCLC.

show abstract

“…EGFR mutations predominantly occur in patients with the features of female sex, non-smoking, adenocarcinoma histology and East Asian ethnicity (Yatabe et al, 2007;Zhang et al, 2013;Usuda et al, 2014). EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, has been proved to be superior to cytotoxic chemotherapy in advanced lung cancer patients carrying the EGFR activating mutation, and EGFR mutation is a good predictor of clinical efficacy of TKIs (Maemondo et al, 2010;Fukuoka et al, 2011).…”

Section: Serummentioning

confidence: 99%

Serum Carcinoembryonic Antigen Levels before Initial Treatment are Associated with EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma Patients

Wang

Li²,

Ma³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Differences in Epidermal Growth Factor Receptor Gene Mutations and Relationship with Clinicopathological Features in NSCLC Between Uygur and Han Ethnic Groups

Cited by 7 publications

References 15 publications

Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China

Prevalence and Clinical Profile of EGFR Mutation In Non-Small-Cell Lung Carcinoma Patients in Southwest China

Lung cancer in never smokers—the East Asian experience

Serum Carcinoembryonic Antigen Levels before Initial Treatment are Associated with EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma Patients

Contact Info

Product

Resources

About